A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease

Coronary Heart Disease Clinical Trial

Official title:

A Randomized, Placebo-controlled, Parallel-group, Investigator- and Participant-blinded Phase 2a Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06031844
• Other study ID #: CDFV890F12201
• Status: Recruiting
• Phase: Phase 2
• Start date: October 16, 2023
• Est. completion date: March 14, 2025

Study information

• Verified date: June 2024
• Source: Novartis
• Contact: Novartis Pharmaceuticals
• Phone: 1-888-669-6682
• Email: novartis.email[@]novartis.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 2a clinical trial will evaluate the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, to reduce key markers of inflammation related to CVD risk, such as IL-6 and IL-18, in approximately 24 people with known heart disease and an elevated marker of inflammation, hsCRP.

Description:

This is a multi-center, randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy, safety, and tolerability of intra-individual dose escalation of DFV890 for inflammatory marker reduction in participants with coronary heart disease and elevated hsCRP. The study consists of a screening period of up to 60 days, a treatment period of approximately 12 weeks, an end of treatment (EOT) visit on Day 85, which is one day after the last dose on Day 84, a follow-up period of approximately 1 week and a standard safety-follow-up call approximately 30 days following the last dose. The overall study duration is approximately 24 weeks and approximately 24 participants will be enrolled into the trial.

Participants meeting all eligibility criteria will be randomized in a 5:5:1:1 ratio to one of four treatment sequences (three DFV890 treatment sequences or a placebo-only sequence). The dose of DFV890 will be uptitrated (according to the specific treatment sequence that the participant is assigned to) approximately every three weeks at the scheduled visits on Days 22, 43 and 64.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: March 14, 2025
• Est. primary completion date: March 6, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Male and female participants aged between 18 - 80 years (inclusive) at the start of screening will be included.

• Subjects must have a body mass index (BMI) within the range of 18 - 40 kg/m2. BMI = Body weight (kg) / [Height (m)]2

• Documented spontaneous myocardial infarction (MI) (diagnosed according to the universal MI criteria with or without evidence of ST segment elevation) at least 30 days before the start of screening.

• Participants must have hsCRP levels = 2 mg/L at two timepoints during screening. Screening values must be separated by a minimum of 8 days. The initial hsCRP value must be a minimum of 30 days after the qualifying MI or after any percutaneous coronary intervention (PCI) performed separately from the qualifying MI.

• For participants on statin therapy (HMG-CoA reductase inhibitor), as clinically indicated, participants must be on a stable regimen (at least 4 weeks before randomization), with no planned statin dose changes over the course of the trial treatment period. Unplanned statin dose changes during the trial treatment period may occur.

Exclusion Criteria:

• Patients receiving concomitant medications that are known to be strong or moderate inducers of cytochrome CYP2C9 enzyme and/or strong inducers of CYP3A, strong inhibitors of CYP2C9 and/or strong or moderate inhibitors of CYP3A and the treatment cannot be discontinued or switched to a different medication within 5 half-lives or 1 week (whichever is longer) prior to Day 1 and for the duration of the study.

• Patients with suspected or proven immunocompromised state at screening

• History of ongoing, chronic, or major recurrent infectious disease, at the discretion of the investigator, at the start of screening.

• Use of any biologic drugs targeting the immune system within 26 weeks of Day 1

• Multi-vessel Coronary Artery Bypass Graft (CABG) surgery within the past 3 years prior to the start of screening.

• Symptomatic Class IV heart failure (New York Heart Association) at the start of screening.

• Planned coronary revascularization (PCI or CABG) or any other major surgical procedure during the study.

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Coronary Heart Disease
• Heart Diseases
• Myocardial Ischemia

Intervention

Drug:
• DFV890
oral film-coated tablets
• Placebo
oral film-coated tablets

Locations

Country	Name	City	State
Canada	Novartis Investigative Site	Montreal	Quebec
Canada	Novartis Investigative Site	Ottawa	Ontario
Canada	Novartis Investigative Site	Sherbrooke	Quebec
United States	Excel Medical Clinical Trials LLC	Boca Raton	Florida
United States	Triad Clinical Trials LLC	Greensboro	North Carolina
United States	University of Florida -Jacksonville UF Health Jacksonville	Jacksonville	Florida
United States	Valley Clinical Trials CPRT128A2302	Northridge	California
United States	Monument Health Clinical Research A Depart Of Monument Health	Rapid City	South Dakota
United States	Universal Research Group LLC Suite 202	Tacoma	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum levels of IL-6 and IL-18	To evaluate the effect of various dose levels of DFV890 versus placebo to reduce circulating levels of inflammatory markers in participants with coronary heart disease and elevated hsCRP	From Day 22 to End of Study Visit (up to 92 days)
Secondary	Plasma trough concentrations (Ctrough) of DFV890 at steady state	To assess the pharmacokinetics of DFV890 in participants with coronary heart disease and elevated hsCRP	From Day 22 to End of Study Visit (up to 92 days)